Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...

Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with ...

A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...

Bupropion conferred modest reductions in cancer-related fatigue compared with placebo, according to results of a randomized ...

Summary: Patients surviving severe traumatic brain injuries often enter states designated as Prolonged Disorders of Consciousness (PDoC) or Locked-In Syndrome (LIS). For decades, standard bedside ...

It's built like a tank and sounds the bomb ...

The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...

BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC) ...

Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...

Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

Read Also: Evommune Stock Cools Off After Big Rally On Successful Eczema Trial Evommune, Inc. EVMN stock is trading lower on ...

NeuroSense Therapeutics Ltd.  ("NeuroSense"), a late-stage clinical biotechnology company focused on developing ...